ClinicalTrials.gg
RecruitingNCT05570474PROMISEUpdated Mar 13, 2024

Effect of Protein Supplementation on Fat Free Mass Preservation After Bariatric Surgery

An interventional study of Protein drink supplementation and Placebo in Bariatric Surgery Candidate, Protein Deficiency and Muscle Loss, sponsored by Maasstad Hospital. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-03-13.

Sponsored by Maasstad Hospital · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Primary completion was expected by Apr 2024, 2 years 7 months ago, but the record still lists the study as recruiting.
  • Started Sep 2022; still recruiting 4 years 2 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
266
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This double blind randomized placebo controlled trial investigates the effect of protein supplementation on fat free mass loss in patients who underwent a Roux-en-Y gastric bypass.

Read the detailed description

Rationale: Protein malnutrition is a severe complication of bariatric surgery and leads to increased morbidity. Previous studies have shown that protein intake and physical activity are the most important factors in the preservation of fat free mass during weight loss. Low protein intake is very common in patients undergoing bariatric surgery despite dietary counselling. Protein powder supplements might help patients to achieve the protein intake recommendations after bariatric surgery and could therefore contribute to preserve fat free mass.

Objective: The main aim of this study is to assess the effect of a daily consumed clear protein powder shake during the first six months after bariatric surgery on fat free mass loss in the first twelve months after laparoscopic Roux-en-Y gastric bypass (LRYGB).

Study design: Double-blind randomized placebo-controlled intervention study

Study population: Patients undergoing LRYGB at the bariatric expertise center for obesity of the Maasstad Hospital Rotterdam.

Intervention and procedure: Inclusion will take place at the outpatient clinic of the bariatric expertise center for obesity of the Maasstad Hospital. Patients will be randomly assigned to either the intervention or control group before surgery. The intervention group will receive a clear protein powder shake of 200 ml containing 20 grams of whey protein which should be taken daily during the first six months after LRYGB. The control group will receive an isocaloric, clear, placebo shake containing maltodextrine.

Main study parameters/endpoints: The main study parameter is the percentage fat free mass loss six months after surgery, calculated as fat free mass loss (kg) divided by total weight loss (kg) x 100%. Fat free mass will be assessed by multi-frequency bioelectrical impedance analysis (MF-BIA). Secondary parameters are percentage fat free mass loss, total weight loss, fat mass loss, BMI, hand grip strength, total protein intake and its progression over time, measured at baseline, 3, 6 and 12 months of follow-up.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: No additional outpatient visits will be required for study participants. A three day food diary and physical activity questionnaire must be filled out by all study participants at five regular follow-up moments. Body composition and handgrip strength will be assessed during these visits. All study participants will be asked to drink a daily shake, either protein or placebo, integrated in their postoperative diet. Study participants will receive information about the changes in body composition after surgery which is considered to be a significant benefit for patients participating in this study. The risk of participation is considered low. The risk consists of a possible allergic reaction to either the protein shake or the placebo.

02

Conditions studied

  • Bariatric Surgery Candidate
  • Protein Deficiency
  • Muscle Loss

Keywords

  • bariatric surgery
  • RYGB
  • Roux-en-Y gastric bypass
  • protein supplementation
  • fat free mass
  • muscle mass
03

In context

Protein Deficiency

20 studies on the registry are indexed under Protein Deficiency; 4 are open to participants now.

This study's planned enrollment of 266 is above the median of 60 across 17 interventional studies indexed under Protein Deficiency.

Browse Protein Deficiency studies →

Lead sponsor

Maasstad Hospital is the lead sponsor of 21 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • Scheduled for a laparoscopic Roux-en-Y Gastric Bypass
  • Age 18 - 65 years
  • ≥ 35 with the presence of severe comorbidity related to morbid obesity (diabetes mellitus type 2, obstructive sleep apnoea syndrome (OSAS), hypertension, etc.) or a BMI ≥ 40 with or without the presence of severe comorbidity related to morbid obesity
  • Written

Exclusion criteria

Exclusion Criteria:

    • Revisional bariatric surgery
  • A protein-restricted diet for medical reasons
  • Diagnosis of a (neuro-) muscular disease
  • Inability to undergo MF-BIA (i.e. pregnancy, pacemaker)
  • Allergy to any of the ingredients of either the protein or the placebo shake
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
266 participants (estimated)

Study arms

  • Experimental
    Protein

    Daily protein shake during 6 months after surgery

    Dietary Supplement: Protein drink supplementation

  • Placebo comparator
    Control

    Daily placebo shake during 6 months after surgery

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementProtein drink supplementation

    Daily drink containing 20 grams of whey protein, dissolved in 200mL water.

  • Dietary supplementPlacebo

    Daily placebo drink

06

What researchers measure

Primary outcomes

  1. Fat Free mass loss

    Main study endpoint is percentage fat free mass loss at 6 months defined as fat free mass loss (kg) divided by total weight loss (kg) x 100%. Fat free mass will be assessed using the Seca® MBCA 515, which is a multi-frequency bio-electrical impedance analysis (MF-BIA). MF-BIA is an easy and non-invasive measurement tool and has been validated in morbid obese patients (13, 14). BIA measurements will be conducted under standardized circumstances. Patients can wear light clothes, have to empty their pockets and have to have an empty bladder. Patients will be asked to have no intensive physical activity and to have no food and fluid intake two hours prior to the measurements to minimalize bias.

    Time frame: Change of fat free mass at 6 months post surgery compared to pre surgery

Secondary outcomes

  1. percentage of fat free mass loss,

    measured by BIA

    Time frame: Change of percentage fat free mass at 6 months post surgery compared to pre surgery

  2. total weight loss,

    measured by BIA

    Time frame: pre surgery, 1 month after surgery, 3 months after surgery, 6 months after surgery, 12 months after surgery

  3. fat mass loss,

    measured by BIA

    Time frame: Change of fat mass at 6 months post surgery compared to pre surgery

  4. BMI

    measured by BIA

    Time frame: Change of BMI at 6 months post surgery compared to pre surgery

  5. hand grip strength,

    measured by hand grip strength device

    Time frame: Change of hand grip strength at 6 months post surgery compared to pre surgery

  6. total protein intake

    measured by 3 day food diary

    Time frame: Change of total protein intake at 6 months post surgery compared to pre surgery

07

Study locations

1 of 1 sites recruiting
  • Maasstad Hospital
    Rotterdam, Zuid Holland 3079DZ, Netherlands
    Recruiting
    • Taselaar, MD · Contact
    • Rene Klaassen, MD · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2022 (actual). Primary completion is estimated for Apr 2024, 19 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2022
First posted
Oct 6, 2022
StartActual
Sep 1, 2022
Primary completionEst.
Apr 1, 2024
CompletionEst.
Dec 1, 2024
Last update
Mar 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05570474
Lead sponsor
Maasstad Hospital
Responsible party
Sponsor
First posted
Oct 6, 2022
Start date
Sep 1, 2022
Primary completion
Apr 1, 2024 (estimated)
Completion
Dec 1, 2024 (estimated)
Last update
Mar 13, 2024

Study contacts

Taselaar, MD
Contact
secretariaatbariatrie@maasstadziekenhuis.nl
0102912246 ext. 0031
Klaassen, MD
principal investigator · Maasstad Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion